Abstract
Autism Spectrum Disorder (ASD) encompasses a range of developmental disabilities marked by differences in social functioning, cognition, and behavior. Both genetic and environmental factors are known to contribute to ASD, yet the exact etiological factors remain unclear. Developing integrative models to explore the effects of gene expression on behavioral and cognitive traits attributed to ASD can uncover environmental and genetic interactions. A notable aspect of ASD research is the sex-wise diagnostic disparity: males are diagnosed more frequently than females, which suggests potential sex-specific biological influences. Investigating neuronal microstructure, particularly axonal conduction velocity offers insights into the neural basis of ASD. Developing robust models that evaluate the vast multidimensional datasets generated from genetic and microstructural processing poses significant challenges. Traditional feature selection techniques have limitations; thus, this research aims to integrate principal component analysis (PCA) with supervised machine learning algorithms to navigate the complex data space. By leveraging various neuroimaging techniques and transcriptomics data analysis methods, this methodology seeks to contextualize the complex genetic and phenotypic heterogeneity linked to sex differences in ASD and pave the way for tailored interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was performed on behalf of the Autism Centers of Excellence GENDAAR Consortium (NIH R01 MH100028; Kevin Archer Pelphrey, Ph.D., PI).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All ACE GENDAAR Wave 1 (9/04/2012-7/31/2022) neuroimaging, phenotypic, and genetic data were collected, processed, and archived on secure local compute servers under the following Internal Review Board (IRB) approvals: USC Approval #HS-13-00668; USC Approval #HS-18-00467; UVA Approval #22078; UVA IRB HSR #21361; GMU #00000169; and UVA #HSR-22-0423. As per the requirements of the US NIMH, de-identified and de-linked copies of all data were regularly submitted to the NDA as part of Collection #2021, where they are freely available for access to approved investigators. Data obtained by subsequent ACE GENDAAR Waves 2 and 3 (ongoing data collection) were not considered in this analysis.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data used in this study is publicly available at: https://nda.nih.gov/edit_collection.html?id=2021
